- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01873898
Clinical Investigation of the Rex Medical -Closer™ Vascular Closure System -Reduced Time to Ambulation Trial
September 26, 2017 updated by: Rex Medical
The purpose of this study is to evaluate the safety and efficacy of the Rex Medical Closer™ Vascular Closure System to close the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures with early ambulation and discharge.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Asuncion, Paraguay
- Centro de IntervencionesEndovasculares Y Cirugia Cardiovascular
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is > 18 years of age.
- Subject is able to undergo diagnostic angiography procedure and is found suitable to receive such a device at the femoral arterial puncture site in order to reduce time to hemostasis.
- Subject or his/her legal guardian understands the nature of the procedure, and provides written informed consent prior to the procedure.
- Subject is available and willing to participate in follow-up through 30 days post femoral closure.
Exclusion Criteria:
- Subject with known allergies to polylactic acid (PLA), polyglycolic acid (PGA) or polydioxanone (PDO) polymers
- Subject with severe acute non-cardiac systemic disease
- Subject with evidence of systemic infection
- Subject where bacterial contamination of the procedural sheath or surrounding tissues may have occurred as this may increase risk of infection
- Subject with coagulopathy (bleeding disorders, including thrombocytopenia, hemophilia, etc.)
- Subject taking thrombolytic medication which reduces fibrinogen to less than 100 mg/dl
- Subject who has had a previous arterial access in the femoral artery on the treatment side with an existing hematoma >5 cm in diameter
- Subject who is unable to ambulate at baseline
- Subject who has had another closure device used in the treatment side within the previous 90 days
- Subject who requires re-entry of the treatment side planned within the next 90 days post-procedure
- Subject has a history of surgical repair on the treatment side
- Subject has planned surgeries for any reason within 90 days post- procedure
- Subject is pregnant or is lactating (non-pregnancy must be confirmed by testing)
- Has a history of a psychiatric condition, substance abuse or alcohol abuse that, in the opinion of the investigator, will potentially interfere with his or her participation
- Subject has been previously enrolled in the Rex Closer™ study
- Subject who is currently or within the previous 4 weeks been enrolled in another investigational device or drug trial
- Subject is incarcerated at the time of enrollment
- Subject where the procedural sheath has been placed through the superficial femoral artery and into the profundafemoris
- Subject where the procedure puncture site is at or distal to the bifurcation of the superficial femoral profundafemoris artery, as this may result in 1) the intravascular sealing patch catching on the bifurcation or being positioned incorrectly, and/or 2) intravascular deployment of the device into the vessel (These events may reduce blood flow through the vessel leading to symptoms of distal arterial insufficiency.)
- Subject's procedure was accessed through a vascular graft
- Subjects with uncontrolled hypertension (> 230 mm Hg systolic)
- Subjects with small femoral artery size (Less than 5 mm in diameter)
- Subjects with stenosis > 50% at the vicinity of the femoral arterial puncture site
- Subjects with anomalous branches or vessel abnormalities present in the vicinity of the femoral arterial puncture site
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
This is a single arm, prospective study to collect data on the safety and effectiveness of the Rex Medical Closer™ Vascular Closure System.
Only subjects who are scheduled to undergo an interventional diagnostic procedure that requires closure of the femoral access site are eligible for study participation.
|
The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath.
This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Ambulation
Time Frame: Day 0
|
Time to Ambulation - in minutes, defined as the time from when hemostasis is achieved to the time when ambulation is achieved (patient standing and walking at least 6.1 meters [20 feet] without re-bleeding).
|
Day 0
|
Frequency of Major Adverse Events through 30 days
Time Frame: 30 days
|
The primary safety endpoint is the frequency of Major Adverse Events through 30 days, defined as one of the following events related to the use of the investigational device: a hematoma requiring a transfusion, a device embolization, false aneurysm requiring intervention or a retroperitoneal bleed.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Hemostasis
Time Frame: Day 0
|
Time to Hemostasis - in minutes, defined as the time from when the delivery system releases both sutures, which are attached to the sealing member, to the time that hemostasis (absence of expanding or developing hematoma) is achieved
|
Day 0
|
Placement Technical Success
Time Frame: Day 0
|
Placement Technical Success - defined as the successful deployment of the device at the intended placement site such that hemostasis is achieved.
|
Day 0
|
Clinical Success
Time Frame: Day 0
|
Clinical Success - evaluated from the time of device deployment, and defined as Placement Technical Success in the absence of any major safety endpoint including subsequent hematoma requiring a transfusion, a device embolization, false aneurysm requiring intervention, or retroperitoneal bleeding.
|
Day 0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Adrian Ebner, MD, Centro de IntervencionesEndovasculares Y Cirugia Cardiovascular
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Actual)
July 1, 2013
Study Completion (Actual)
July 1, 2013
Study Registration Dates
First Submitted
June 6, 2013
First Submitted That Met QC Criteria
June 7, 2013
First Posted (Estimate)
June 10, 2013
Study Record Updates
Last Update Posted (Actual)
September 28, 2017
Last Update Submitted That Met QC Criteria
September 26, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- REX-OUS-2027-004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bleeding
-
Ethicon, Inc.Guangzhou Bioseal Biotechnology Co., Ltd.Completed
-
Waihong ChungUnknownMetoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy (MANPURSE)Upper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Ottawa Hospital Research InstituteRecruitingGastroIntestinal Bleeding | Anticoagulant-induced BleedingCanada
-
Ethicon, Inc.CompletedHemorrhage | Soft Tissue Bleeding | Hepatic Parenchyma BleedingUnited Kingdom, Belgium
-
Hyloris DevelopmentsRecruitingBleeding From Teeth | Bleeding ProphylaxisSpain, United States, Belgium, Croatia, Hungary, Romania
-
Boston Children's HospitalBaylor College of Medicine; Children's Hospital of Philadelphia; Ann & Robert... and other collaboratorsRecruitingUpper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Wake Forest University Health SciencesCompletedBleeding ComplicationUnited States
-
Chinese University of Hong KongCompletedGastrointestinal Bleeding | Bleeding Peptic Ulcer | Active BleedingChina
-
Chinese University of Hong KongBeijing Friendship Hospital; The First Affiliated Hospital of Soochow University and other collaboratorsCompletedAcute Upper Gastrointestinal Bleeding | Tumor BleedingHong Kong, China, Australia
-
Women and Infants Hospital of Rhode IslandActive, not recruitingAbnormal Uterine Bleeding | Abnormal Uterine Bleeding, Ovulatory Dysfunction | Abnormal Uterine Bleeding, Endometrial Hemostatic DysfunctionUnited States
Clinical Trials on Rex Medical Closer™ Vascular Closure System
-
Rex MedicalCompletedSurgical WoundUnited States
-
Cordis CorporationCompletedCoronary Arteriosclerosis | Angioplasty, Transluminal, Percutaneous CoronaryGermany
-
Cardiva Medical, Inc.CompletedSurgical WoundUnited States, Australia
-
Medstar Health Research InstituteCardinal HealthCompletedCardiac Diagnostic Procedure | Cardiac Interventional Procedure | Femoral Access Site ClosureUnited States
-
Taewoong Medical Co., Ltd.TerminatedThe Patients Who Needed Hemostasis at the Puncture Site of Common Femoral Artety(CFA) Caused by Femoral Angiogram or Intervention After the Catheter RemovalKorea, Republic of
-
Cordis CorporationNAMSACompletedVenous Vascular ClosureUnited States
-
Medtronic EndovascularCompleted
-
Lake Washington VascularSyntactxCompletedVenous RefluxUnited States
-
Coherex MedicalTerminatedPatients With Migraine and PFO
-
Lifetech Scientific (Shenzhen) Co., Ltd.Not yet recruitingAneurysm | Portal Hypertension | Arteriovenous Fistula | Endoleak | Pulmonary Arteriovenous Malformation | Splenic Laceration